Abstract: Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Abstract: The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Abstract: Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Abstract: The present disclosure is directed toward drugs and toxins functionalized by at least one saccharide, sulfate or sulfonate; drug conjugates comprising said drugs or toxins and a cleavable linker; and targeted conjugates comprising said drugs or toxins, cleavable linkers, and targeting moieties. The present disclosure also relates to methods of treating cancers, auto-immune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.

Abstract: The invention relates to activated Michael acceptor (AMA) compounds that can undergo conjugation with biomolecules containing Michael donor moieties, thereby providing plasma-stable antibody-drug conjugates (ADCs). Pharmaceutical compositions of the ADCs are disclosed as well. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

Abstract: The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Abstract: Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Abstract: Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a —S(?O)(?N—)- functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Abstract: Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Abstract: The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g.

Abstract: According to one embodiment, a dual voltage controlled oscillator (VCO) circuit includes a first VCO and a second VCO. The first VCO includes: a first variable capacitor having an input node, a first output node, and a second output node, a second variable capacitor coupled in parallel with the first variable capacitor, a first transistor, and a second transistor, where the first transistor has a first drain coupled to the first output node, a first gate coupled to the second output node, and a first source coupled to a ground, where the second transistor has a second drain coupled to the second output node and a second gate coupled to the first output node, and a second source coupled to the ground. The dual VCO circuit includes a second VCO mirroring the first VCO, a first and a second inductors coupled to the first and the second VCO respectively.

Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).

Abstract: The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Abstract: According to one embodiment, a dual voltage controlled oscillator (VCO) circuit includes a first VCO and a second VCO. The first VCO includes: a first variable capacitor having an input node, a first output node, and a second output node, a second variable capacitor coupled in parallel with the first variable capacitor, a first transistor, and a second transistor, where the first transistor has a first drain coupled to the first output node, a first gate coupled to the second output node, and a first source coupled to a ground, where the second transistor has a second drain coupled to the second output node and a second gate coupled to the first output node, and a second source coupled to the ground. The dual VCO circuit includes a second VCO mirroring the first VCO, a first and a second inductors coupled to the first and the second VCO respectively.

Abstract: According to one embodiment, a phase locked loop (PLL) circuit includes a first voltage controlled oscillator (VCO) to generate a first signal having a first frequency and a second VCO to generate a second signal having a second frequency. The PLL circuit includes a multiplexer coupled to the first VCO, the second VCO, and a feedback loop. The PLL circuit includes a control logic to select either the first VCO or the second VCO using the multiplexer to feed back a signal using the feedback loop, and a phase frequency detector coupled to the first VCO, the second VCO, and the feedback loop, where the phase frequency detector is configured to receive a reference signal and the feedback signal to tracking a frequency and a phase of the first or the second generated signal using the reference signal and the feedback signal.

Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).

Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g.